Evidence map›Paper›PMID 40072570›Full record

ArticleWorld journal of urology2025

Comparing oncologic outcomes of partial and radical nephrectomy for T2 renal cell carcinoma: a propensity score matching cohort study and an external multicenter validation.

Weipu Mao, Tiange Wu, Sagar Barge, Muhammad Zubair, Daniel Sanchez, Jiang Geng, Atrayee Bhattacharya, Ming Chen

Abstract readMulticenter StudyComparative StudyValidation Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weipu Mao *Department of Urology, Zhongda Hospital Southeast University, Nanjing, China.
Tiange Wu *Department of Urology, Zhongda Hospital Southeast University, Nanjing, China.
Sagar Barge *Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Muhammad ZubairDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Daniel SanchezDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. desa6957@gmail.com.
Jiang GengDepartment of Urology, Bengbu First People's Hospital, Bengbu, China. gengjiangsn@sina.com.
Atrayee BhattacharyaDepartment of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. atrayee_bhattacharya@dfci.harvard.edu.
Ming ChenDepartment of Urology, Zhongda Hospital Southeast University, Nanjing, China. mingchenseu@126.com.

Funding

Jiangsu Provincial Medical Key Discipline ZDXK202220National Natural Science Foundation of China 82403602Natural Science Foundation of Jiangsu Province BK20230842Research Personnel Cultivation Programme of Zhongda Hospital Southeast University CZXM-GSP-RC60Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds GSP-LCYJFH21
6 · The paper itself

Abstract

purposeThere is very limited evidence on the optimal surgical treatment for patients with larger T2 renal tumors. This study aims to evaluate the oncologic outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) in T2 renal cell carcinoma (RCC).

methodsA retrospective data analysis was conducted on T2 RCC patients who underwent PN or RN between 2004 and 2019 using the SEER database, and validated with data from multiple centers in China from 2014 to 2019. Kaplan-Meier survival curves and multivariate Cox regression analysis were performed to assess the treatment effects of PN and RN.

resultsThe Kaplan-Meier survival curves showed that both in the SEER database and Chinese multicenter data, PN was associated with a higher overall survival (OS) compared to RN in the all patients, male and age ≤ 60 years groups after propensity score matching. The multivariate Cox regression analysis indicated that PN benefited the OS in the all patients (RN vs. PN, HR = 1.476; 95% CI, 1.113-1.957; P = 0.007), and T2a age ≤ 60 years subgroup (RN vs. PN, HR = 2.147; 95% CI, 1.228-3.754; P = 0.007).

conclusionPN is a viable treatment option for patients with T2 RCC, particularly for patients with T2a age ≤ 60 years, where PN is associated with a higher OS rate. However, patients with stage T2 tumors undergoing PN should be referred to high-volume centers for treatment.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNephrectomyAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedNeoplasm StagingPropensity ScoreRetrospective StudiesSurvival RateTreatment OutcomeOncologic outcomesPartial nephrectomyPropensity score matchingRadical nephrectomyT2 renal cell carcinoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.